Loading clinical trials...
Loading clinical trials...
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT02446132 · Agitation in Patients With Dementia of the Alzheimer's Type
NCT04464564 · Agitation in Patients With Dementia of the Alzheimer's Type
NCT03393520 · Agitation in Patients With Dementia of the Alzheimer's Type
NCT04797715 · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, and more
NCT03226522 · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, and more
Clinical Research Site
Phoenix, Arizona
Clinical Research Site
Scottsdale, Arizona
Clinical Research Site
Little Rock, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions